Concomitant blockade of both Notch1, via anti-N1, and ChK1, via prexasertib (prex), a ChK1/2 inhibitor currently in several phase 2 clinical trials [16–18], exacerbates DNA damage increasing melanoma cell death. This evidence concerns the gene NOTCH1 and melanoma.